Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2
pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and
Cohort 4, Cohort 5 and Cohort 6).
The primary objectives of this study are:
- Phase 1 Study: Evaluate the safety of axicabtagene ciloleucel regimens
- Phase 2 Pivotal Study; Evaluate the efficacy of axicabtagene ciloleucel
- Phase 2 Safety Management Study: Assess the impact of prophylactic regimens or earlier
interventions on the rate and severity of cytokine release syndrome (CRS) and neurologic
toxicities
Subjects who received an infusion of KTE-C19 will complete the remainder of the 15 year
follow-up assessments in a separate long-term follow-up study, KT-US-982-5968.
Phase
Phase 1/Phase 2
Funding Agency/Sponsor
Industrial
Disease
Lymphoma
Enrollment Eligibility
Key Inclusion Criteria
1. Histologically confirmed:
- Diffuse Large B Cell Lymphoma (DLBCL)
- Primary Mediastinal Large B Cell Lymphoma (PMBCL)
- Transformation Follicular Lymphoma (TFL)
- High grade B-cell lymphoma (HGBCL)
2. Chemotherapy-refractory disease, defined as one of more of the following:
- No response to last line of therapy i. Progressive disease (PD) as best response
to most recent therapy regimen ii. Stable disease (SD) as best response to most
recent therapy with duration no longer than 6 month from last dose of therapy OR
- Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or
relapsed less than or equal to 12 months of ASCT (must have biopsy proven
recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT,
the individual must have had no response to or relapsed after the last line of
therapy
3. Individuals must have received adequate prior therapy including at a minimum:
- anti-CD20 monoclonal antibody unless investigator determines that tumor is
CD20-negative and
- an anthracycline containing chemotherapy regimen
- for individual with transformed FL must have chemorefractory disease after
transformation to DLBCL.
4. At least one measurable lesion per revised IWG Response Criteria
5. Eastern cooperative oncology group (ECOG) performance status of 0 or 1
6. Absolute neutrophil count (ANC) ≥ 1000/uL
7. Absolute lymphocyte count ≥ 100/uL
8. Platelet count ≥ 75,000/uL
9. Adequate renal, hepatic, pulmonary and cardiac function defined as:
- Creatinine clearance (as estimated by Cockcroft Gault) > 60 mL/min
- Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 upper
limit of normal (ULN)
- Total bilirubin < 1.5 mg/dL, except in individuals with Gilbert's syndrome
- Cardiac ejection fraction >50%, no evidence of pericardial effusion as determined
by an echocardiogram (ECHO), and no clinically significant pleural effusion
- Baseline oxygen saturation >92% on room air
10. All individuals or legally appointed representatives/caregivers, must personally sign
and date the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
approved consent form before initiating any study specific procedures or activities.
11. Relapsed or refractory large B-cell lymphoma including DLBCL, PMBCL, TFL, and HGBCL
after two systemic lines of therapy
Key Exclusion Criteria
1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g.
cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3
years
2. History of allogeneic stem cell transplantation
3. Prior CAR therapy or other genetically modified T cell therapy
4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
requiring IV antimicrobials for management. Simple urinary tract infection (UTI) and
uncomplicated bacterial pharyngitis are permitted if responding to active treatment
5. History of human immunodeficiency virus (HIV) infection or acute or chronic active
hepatitis B or C infection. Individuals with history of hepatitis infection must have
cleared their infection as determined by standard serological and genetic testing per
current Infectious Diseases Society of America (IDSA) guidelines
6. Individuals with detectable cerebrospinal fluid malignant cells, or brain metastases,
or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma,
cerebrospinal fluid malignant cells or brain metastases
7. History or presence of CNS disorder such as seizure disorder, cerebrovascular
ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS
involvement
Note: Other protocol defined Inclusion/Exclusion criteria may apply.